[16th EORTC-NCI-AACR symposium on new molecular targets and cancer therapeutics].
Lavelle
François
F
Société Française du Cancer, 14, rue Corvisart, 75013 Paris. francoise.lavelle@wanadoo.fr
D000123:Acetyltransferases / Q000037:antagonists & inhibitors; D017209:Apoptosis / Q000187:drug effects; D015687:Cell Hypoxia; D000068338:Everolimus; D051548:Histone Acetyltransferases; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors; D051057:Proto-Oncogene Proteins c-akt; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; C401859:temsirolimus; D000068338:Everolimus; D000123:Acetyltransferases; D051548:Histone Acetyltransferases; D011505:Protein-Tyrosine Kinases; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D020123:Sirolimus